Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital-Reference-Cited by-同舟云学术

Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital

Published:2024-02 Issue: Volume:171 Page:116181
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Elizalde Mikel Urroz,Eguinoa Francisco Javier Guijarro,de las Huertas Arturo Gómez López,Jiménez-González María,Ramírez Elena^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference40 articles.

1. World Health Organisation. WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020. Available at: 〈https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020〉 [Accessed September 1, 2023].

2. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020" World Health Organization (WHO). March 11, 2020] Available at 〈https://www.who.int/es/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020〉 [Accessed September 1, 2023].

3. Nota de prensa, Ministerio de Sanidad y Consumo del Gobierno de España. Available at [Press release, Ministry of Health and Consumer Affairs of the Government of Spain]. Available at 〈https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=5182〉 [Accessed September 1, 2023].

4. Comirnaty. Summary of Product Characteristics. Available at: 〈https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf〉 [Accessed September 1, 2023].

5. Spikevax. Summary of Product Characteristics. Available at: 〈https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf〉 [Accessed September 1, 2023].